# Quanterix Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Quanterix Corp). ## Overview Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples. Its portfolio includes Simoa-based instruments, consumables, and the Accelerator Laboratory service platform, with customers served through direct sales and distribution channels in North America, Europe, and other international markets. ## Products & services • Simoa bead-based instruments • Planar array instrument systems • Assay kits and consumables • Accelerator Laboratory services • Spatial biology instruments and solutions • Diagnostic and research collaboration services - **Instruments** (20%) — Analytical instruments used for proteomics, biomarker detection, and spatial biology workflows. - **Consumables and assay kits** (55%) — Reagents, bead-based consumables, and assay kits used with installed instruments. - **Services** (25%) — Accelerator Laboratory and other research or collaboration services. - Simoa bead-based instruments - Planar array instrument systems - Assay kits and consumables - Accelerator Laboratory services - Spatial biology instruments and solutions - Diagnostic and research collaboration services ## Customers Quanterix sells primarily to life science researchers, pharmaceutical and biotech companies, and clinical research organizations that need highly sensitive protein measurement tools. It also serves academic and government research customers, and increasingly supports diagnostic-oriented applications through collaborations and test commercialization efforts. - **Pharmaceutical and biotech R&D** (primary) — Buys instruments, consumables, and services for biomarker discovery and clinical research. - **Academic and government research** (primary) — Uses Simoa systems and assays for basic and translational research applications. - **Clinical research organizations** (secondary) — Outsources specialized testing and laboratory services for sponsored studies. - **Diagnostic and clinical partners** (secondary) — Evaluates assays and platforms for future diagnostic or LDT applications. - Pharmaceutical companies buying biomarker tools for R&D and trials - Biotech and translational research teams needing sensitive protein assays - Academic and government labs using instruments for discovery research - Clinical research organizations outsourcing specialized testing and services - Diagnostic partners evaluating assays for future clinical use ## Geography Quanterix operates with a global customer base, with a substantial share of revenue generated outside North America. The company maintains sales, support, and marketing personnel primarily in North America and Europe, and it is building distribution and support capabilities in China and broader APAC markets. - **North America** (64%) — Implied by disclosure that ~36% of revenue came from outside North America in prior years. - **Outside North America** (36%) — Management disclosed approximately 36% of revenue from customers outside North America for 2024. - Revenue is materially international, with customers outside North America - Sales and support staff are concentrated in North America and Europe - China and APAC are targeted for broader distribution and support coverage - Manufacturing is split between in-house facilities and third-party partners - International sales depend on distributors, local compliance, and service coverage ## Strategy Quanterix is focused on expanding its installed base, launching new instruments and tests, and extending its platform into diagnostics and spatial biology. It also emphasizes global distribution, customer support, and collaborations with key opinion leaders to strengthen adoption and defend its position in sensitive biomarker measurement. - **Commercialize new instruments and assays** (short-term) — New products are central to replacing aging systems and sustaining platform relevance. - **Expand diagnostics and clinical applications** (medium-term) — Diagnostic use cases can broaden the addressable market beyond research customers. - **Build international distribution coverage** (medium-term) — International markets are a meaningful source of growth and require local support. - **Strengthen customer retention and installed-base utilization** (short-term) — Consumables and service revenue depend on active instrument usage and repeat demand. - Expand the installed base to drive recurring consumables demand - Commercialize new instruments and next-generation platform offerings - Advance diagnostic applications, including LucentAD Complete - Broaden international distribution and support, especially in APAC - Use collaborations and key opinion leaders to support adoption ## Risks Quanterix faces competition from larger life science instrument companies and smaller specialists across proteomics, spatial biology, and diagnostics. Its results are also exposed to customer concentration, international execution risk, product development delays, and accounting/control issues tied to acquisitions and complex estimates. - **Competitive pressure from larger and specialized rivals** [high] — The company competes with firms such as Bio-Techne, 10x Genomics, Bruker, and others across multiple platforms. - **Customer concentration** [high] — A meaningful portion of revenue comes from a limited number of large customers, increasing volatility if one reduces spend. - **International execution and compliance risk** [medium] — Growth outside North America depends on distributors, foreign regulations, and anti-bribery compliance. - **Product development and launch delays** [high] — Technical challenges or supply chain issues could slow commercialization of next-generation instruments. - **Acquisition integration and internal control risk** [high] — Integrating acquired businesses and remediating control weaknesses can create reporting and execution risk. - Competition is intense across proteomics, spatial biology, and diagnostics - A few large customers can materially affect revenue if demand weakens - International growth depends on distributors, compliance, and local execution - New product launches can be delayed by technical or manufacturing issues - Acquisition integration and internal control weaknesses can distort results ## Accounting Revenue is split across instruments, consumables, services, and collaboration or license arrangements, so timing and contract terms can materially affect quarterly results. Investors should also watch acquisition accounting, including goodwill, intangible assets, off-market contract assets and liabilities, contingent consideration, and any impairment testing tied to acquired businesses. - **Revenue recognition across multiple revenue streams** — Quarterly mix and timing can shift reported revenue materially - **Acquisition accounting for Akoya and other deals** — Can affect revenue, amortization, and impairment risk - **Goodwill and intangible asset impairment** — Potential non-cash charges if expected benefits do not materialize - **Contingent consideration and fair value estimates** — Can create earnings volatility through remeasurement - Revenue timing differs across instruments, consumables, services, and licenses - Acquisition accounting creates goodwill and intangible asset balances - Off-market contract assets and liabilities can affect reported service revenue - Contingent consideration and fair value estimates can move earnings - Internal control weaknesses raise the risk of misstatement in reported results --- *Last updated: 2026-04-29T04:50:41.771764+00:00*